Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...

German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from ...

German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

Sanofi reports positive Phase III results for a subcutaneous version of Sarclisa in relapsed or refractory multiple myeloma.

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to ...

UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on ...

Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and ...

Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and ...

Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research ...

Netherlands-based Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic ...